Related Experiment Video

Updated: May 20, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib for lung cancer: is the "Battle" still open?

Emilio Bria, Sara Pilotto, Giampaolo Tortora

    Expert Opinion on Investigational Drugs
    |July 18, 2012
    PubMed

    Insights

    Tyrosine kinase inhibitors (TKIs) show promise in cancer treatment by targeting angiogenesis, a key process in tumor growth. Sorafenib, a multi-targeted TKI, is approved for advanced renal cell and hepatocellular carcinoma, with ongoing research in non-small cell lung cancer.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Angiogenesis is a critical hallmark of cancer, driving tumor growth and progression.
    • Anti-angiogenic drugs, including tyrosine kinase inhibitors (TKIs), represent a promising therapeutic strategy.
    • Sorafenib is a multi-targeted TKI approved for advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).

    Discussion:

    • TKIs, such as Sorafenib, Sunitinib, Pazopanib, and Axitinib, are designed to inhibit angiogenesis.
    • Multi-targeted TKIs like Sorafenib inhibit multiple pathways crucial for tumor development and progression.
    • The multi-targeted nature of TKIs may enhance efficacy but also potentially increase toxicity.

    Key Insights:

    • Sorafenib's multi-targeted action inhibits critical tumor growth pathways.
    • Approved indications for Sorafenib include advanced RCC and HCC.
    • Sorafenib is under investigation for advanced non-small cell lung cancer (NSCLC).

    Outlook:

    • Further research is needed to fully understand the efficacy and toxicity profiles of multi-targeted TKIs.
    • Combination therapies involving TKIs may offer improved outcomes for various cancers.
    • Investigating Sorafenib in NSCLC, alone or in combination, could lead to new treatment options.

    More Related Videos

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...